Top Page
Intelligent Bio Solutions
(NASDAQ:INBS)
Intelligent Bio Solutions (INBS) vs. SPDR S&P 500 ETF (SPY)
Intelligent Bio Solutions Business Overview & Revenue Model
Intelligent Bio Solutions Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.05M | 3.05M | 3.11M | 1.26M | 0.00 | 1.98M |
| Gross Profit | 1.25M | 1.25M | 1.43M | 326.67K | 0.00 | 1.98M |
| EBITDA | -9.33M | -9.34M | -8.81M | -9.47M | 30.82K | -1.82M |
| Net Income | -10.57M | -10.57M | -10.16M | -10.63M | -8.31M | -7.04M |
Balance Sheet | ||||||
| Total Assets | 8.25M | 8.25M | 13.78M | 10.35M | 12.35M | 20.40M |
| Cash, Cash Equivalents and Short-Term Investments | 1.02M | 1.02M | 6.30M | 1.54M | 8.24M | 12.57M |
| Total Debt | 281.81K | 281.81K | 871.44K | 1.34M | 0.00 | 0.00 |
| Total Liabilities | 5.44M | 5.44M | 5.60M | 6.67M | 5.81M | 6.85M |
| Stockholders Equity | 3.00M | 3.00M | 8.33M | 3.80M | 6.62M | 13.61M |
Cash Flow | ||||||
| Free Cash Flow | -9.91M | -9.91M | -9.79M | -7.88M | -3.74M | -11.30M |
| Operating Cash Flow | -9.68M | -9.68M | -9.57M | -7.38M | -3.36M | -11.30M |
| Investing Cash Flow | -231.84K | -231.84K | -221.43K | -694.14K | -880.22K | 0.00 |
| Financing Cash Flow | 4.60M | 4.60M | 14.56M | 1.44M | 0.00 | 23.40M |
Intelligent Bio Solutions Technical Analysis
Intelligent Bio Solutions Risk Analysis
Intelligent Bio Solutions Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $7.52M | ― | ― | ― | ― | ― | |
41 Neutral | $6.36M | -0.07 | -303.74% | ― | -43.77% | 55.78% | |
39 Underperform | $7.65M | ― | -186.64% | ― | -1.90% | 87.72% | |
38 Underperform | $9.40M | -0.10 | -1802.45% | ― | 4.99% | 22.58% | |
26 Underperform | $9.13M | ― | ― | ― | ― | ― |
Intelligent Bio Solutions Corporate Events
On October 30, 2025, Intelligent Bio Solutions Inc. announced the addition of 33 new customer accounts during its fiscal first quarter ending September 30, 2025, marking a 50% increase from the previous year. This growth, particularly strong in the UK and supported by distributor activity in Europe and the Middle East, brings the total active accounts to over 480. The company’s expansion into sectors like government administration highlights the broadening applicability of its solutions. Approximately 91% of new accounts were first-time adopters of the company’s drug screening solution, indicating strong market penetration and customer confidence. The global drug screening market is projected to grow significantly, positioning Intelligent Bio Solutions to capitalize on this opportunity and drive sustainable revenue growth.
The most recent analyst rating on (INBS) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
On October 16, 2025, Intelligent Bio Solutions Inc. held its annual meeting of stockholders, where an amendment to the 2019 Long Term Incentive Plan was approved, increasing the shares available for issuance by 495,000. The meeting also saw the election of directors, ratification of UHY LLP as the accounting firm, and approval of several proposals including a reverse stock split and issuance of shares upon warrant exercise.
The most recent analyst rating on (INBS) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
On September 26, 2025, Intelligent Bio Solutions announced an update on their timeline for FDA 510(k) clearance of their Intelligent Fingerprinting Drug Screening System for codeine. Following feedback from the FDA, the company plans to initiate clinical studies by the end of 2025, aiming for clearance in the second half of 2026. This strategic move is expected to enhance their market positioning by expanding their product’s reach into the U.S. market, beyond its current forensic use, while maintaining growth in international markets.
The most recent analyst rating on (INBS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
On September 20, 2025, Intelligent Bio Solutions Inc. announced the extension of the termination date for its Series H-1 Common Stock Purchase Warrants from September 27, 2025, to March 27, 2026. This decision, which does not alter the exercise prices or other terms, was made with the consent of all six warrant holders, affecting 1,034,213 shares of common stock, and was executed without any additional consideration or agreements.
The most recent analyst rating on (INBS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
On September 17, 2025, Intelligent Bio Solutions announced that the FDA requested additional information for its Intelligent Fingerprinting Drug Screening System, necessitating a resubmission of the 510(k) notification. This request follows the company’s initial submission in December 2024 and subsequent responses to over 70 questions in August 2025. The FDA’s feedback is part of the process for this first-of-its-kind device, and the company remains confident in its technology’s capabilities. While awaiting U.S. clearance, Intelligent Bio Solutions continues to expand its international business, maintaining commercial progress globally.
The most recent analyst rating on (INBS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
On August 6, 2025, Intelligent Bio Solutions Inc. announced the submission of additional information to the FDA as part of its 510(k) clearance process, aiming for U.S. market entry later in the year. The submission includes extensive cybersecurity and performance data, reinforcing the company’s fingerprint sweat-based drug screening technology. This move is a critical step in the company’s U.S. expansion strategy, with the potential to significantly impact its market presence and commercial opportunities in the multi-billion-dollar U.S. market. The company expects a response from the FDA within six weeks.